Global Angiogenesis Inhibitors Market, By Product (VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading and Remodeling Targeted Therapy, Others), Indication (Glioblastoma, Colorectal Cancer and Others), Drugs (Inlyta, Avastin, Revlimid and others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029
Global Angiogenesis Inhibitors Market Analysis and Insights
The high prevalence of the different types of cancer affecting number of people is expected to help the angiogenesis inhibitors market to experience tremendous growth within the forecast period. Moreover, the market is expected to show a negative growth within the forecast period due to the effects of restrictions caused by sudden outbreak of COVID-19.
- Data Bridge Market Research analyses that the angiogenesis inhibitors market will grow at a CAGR of 9.20% during the forecast period of 2022 to 2029. The “VEGF targeted therapy” accounts for the product segment in the angiogenesis inhibitors market within the forecasted period.
Global Angiogenesis Inhibitors Market Definition
The formation of new blood vessels is known as angiogenesis. Anti-angiogenics, also referred as angiogenesis inhibitors, are substances that block the process of angiogenesis. These drugs are crucial in the treatment of certain cancers. Angiogenesis inhibitors are different from other cancer-fighting drugs in that they stop the growth of blood vessels that support tumor growth rather than stopping tumor cells from growing.
Angiogenesis Inhibitors Market Dynamics
- Growing Cases of Cancer
The increasing burden of cancer such as breast cancer, prostate cancer and lung cancer globally will result in the expansion of the growth rate of the treatment market.
Moreover, the research and development investments generates novel therapies are also the growth determinants which bolster the growth of the market. Also, the availability of treatment options and robust pipeline that leads to potential drugs will further enhance the growth of angiogenesis inhibitors market.
Furthermore, advancement in medical technology and rise in the increasing adverse effects from chemotherapy are the cancer that will expand the angiogenesis inhibitors market. Other factors such as increase in the demand for effective treatment procedures will positively impact the angiogenesis inhibitors market's growth rate.
Moreover, the government initiatives to increase cancer awareness will boost new opportunities for the market's growth rate. Also, the developments in healthcare technology will escalate the growth rate angiogenesis inhibitors market in future.
Restraints/Challenges Global Angiogenesis Inhibitors Market
However, the high cost of the inhibitor will impede the growth rate of angiogenesis inhibitors market. Additionally, the stringent government regulations hampers the market growth.
This angiogenesis inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on angiogenesis inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Angiogenesis inhibitors, are substances that block the process of angiogenesis. The annual cancer cases are expected rise from14 million to 22 million in next two decades.
Angiogenesis inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Angiogenesis Inhibitors Market
The senior population with underlying severe therapeutic conditions, including people with cancer along with the patients with hepatocellular carcinoma might be at higher risk for severe illness from COVID-19 thus influencing market at a high level. Pharmaceutical industries were heavily impacted by the COVID-19. The angiogenesis inhibitors market was however affected negatively by the sudden emergence of the COVID-19, due to suspended of various operations which are not emergency cases as a result of several government restrictions. Moreover, the disruption in supply chain causing delays in the import and export of drugs and medicines for the angiogenesis inhibitors also further creates hurdles for the expansion of the market.
- In June 2020, Targovax, a biotechnology company, has teamed up with Leidos' Explorations in Global Health (ExGloH) division to see if ONCOS, a Targovax clinical programme of oncolytic adenoviruses, can be used as a vector to encode MicrotideT checkpoint inhibitor peptides. MicrotideTM is a proprietary portfolio of microbially-derived peptides that act as immune checkpoint inhibitors developed by Leidos' Explorations in Global Health (ExGloH) division. Leidos is a defence, aviation, information technology, and biomedical research company based in the United States.
Global Angiogenesis Inhibitors Market Scope
The angiogenesis inhibitors market is segmented on the basis of product, indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- VEGF Targeted Therapy
- FGF Targeted Therapies
- Oncogene Targeted Therapy
- Matrix Degrading and Remodeling Targeted Therapy
On the basis of product, angiogenesis inhibitors market is segmented into VEGF targeted therapy, FGF targeted therapies, oncogene targeted therapy, matrix degrading and remodeling targeted therapy and others. VEGF targeted therapy segment is expected to grow at the fastest CAGR during the forecast period.
- Colorectal Cancer
On the basis of indication, angiogenesis inhibitors market is segmented into glioblastoma, colorectal cancer and others.
Route of Administration
On the basis of route of administration, the angiogenesis inhibitors market is segmented into oral, parenteral and others.
- Specialty Clinics
On the basis of end-users, the angiogenesis inhibitors market is segmented into hospitals, specialty clinics and others.
- Hospital Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the angiogenesis inhibitors market is segmented into hospital pharmacy, retail pharmacy and others.
Angiogenesis Inhibitors Market Regional Analysis/Insights
The angiogenesis inhibitors market is analyzed and market size insights and trends are provided by country, product, indication, drugs, route of administration, end-users and distribution channel as referenced above.
The countries covered in the angiogenesis inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the angiogenesis inhibitors market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing incidence of cancer in the country, the presence of key market players, and the launch of new commodities influence market growth in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the factors such as the surging awareness about early diagnosis, growth in healthcare expenditure, high unmet clinical needs of patients as well as the effective treatment in emerging countries such as China and India in the region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Angiogenesis Inhibitors Market Share Analysis
The angiogenesis inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angiogenesis inhibitors market.
Some of the major players operating in the angiogenesis inhibitors market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Exelixis, Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Melinta Therapeutics LLC, Cipla Inc., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Balaji Medical Services Private Limited, Eli Lilly and Company, Bayer AG, Sanofi and Merck & Co., among others.
Research Methodology : Global Angiogenesis Inhibitors Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-angiogenesis-inhibitors-market